GP681 Simulant

DRUG3 trials

Sponsors

Jiangxi Qingfeng Pharmaceutical Co. Ltd.

Conditions

InfluenzaInfluenza, Human

Phase 2

A Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Uncomplicated Acute Influenza

CompletedNCT04736758

Jiangxi Qingfeng Pharmaceutical Co. Ltd.Influenza

Start: 2021-01-08End: 2021-12-18Updated: 2022-07-26

Phase 3

Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications

RecruitingNCT06573008

Jiangxi Qingfeng Pharmaceutical Co. Ltd.Influenza, Human

Start: 2024-11-11End: 2025-12-30Target: 328Updated: 2024-12-04

Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza

RecruitingNCT06574503

Jiangxi Qingfeng Pharmaceutical Co. Ltd.Influenza

Start: 2024-12-01End: 2027-12-30Target: 748Updated: 2024-12-05

Related Papers

Efficacy and safety of single-dose suraxavir marboxil tablet in the treatment of acute uncomplicated influenza in adults: a multi-centre, randomized, double-blind, placebo-controlled phase 2 clinical trial.

2025-01-252 citations